FOXO Technologies Inc. - FOXO STOCK NEWS

FOXO Technologies Inc. has launched its Bioinformatics Services to accelerate breakthroughs in biology, biotechnology, and healthcare. The services offer advanced data solutions tailored to meet the needs of clients in academia, healthcare, and pharmaceutical research. By leveraging state-of-the-art algorithms and experts, FOXO aims to eliminate barriers in data processing, analysis, and interpretation, empowering researchers and organizations to accelerate their research.

FOXO Technologies Inc. received a notice of noncompliance from NYSE stating that the Company is below compliance with Section 1003(a)(i) in the NYSE American Company Guide. The Company has until July 12, 2023, to submit a plan advising of actions it will take to regain compliance with the continued listing standards.

FOXO Technologies Inc. (NYSEAM: FOXO) has launched its beta version of the FOXO Longevity Report, a direct-to-consumer wellness product. This innovative report utilizes epigenetic biotechnology and AI to analyze saliva samples, offering health insights across metabolism, inflammation, cardiovascular health, and indulgences. By examining nearly one million sites in the epigenome, the report provides a detailed health assessment, surpassing traditional genetic analysis methods. Interim CEO Tyler Danielson emphasized the report's potential for personal health improvement and the company's commitment to advancing health outcomes through technology. The Longevity Report is now available for purchase, with early adopters receiving product upgrades and insights at no additional cost. FOXO aims to leverage extensive epigenetic data sets to optimize healthspan and lifespan.

FOXO Technologies Inc. announced the resignation of Chief Operating Officer Taylor Fay, effective April 28, 2023. Interim CEO Tyler Danielson praised Fay's leadership, stating the company benefited from his contributions. Fay expressed pride in his time at FOXO and remains supportive of the company's future. FOXO specializes in epigenetic biomarkers related to health and aging, aiming to enhance human longevity through innovative biotechnology solutions. The company applies AI to DNA methylation for health assessments, positioning itself within the life insurance industry among others.

In this announcement, FOXO emphasizes its commitment to leveraging scientific advancements for improved health outcomes, although there are inherent risks associated with the biotechnology sector.

FOXO Technologies Inc. (NYSEAM: FOXO) reported financial results for the full year 2022, emphasizing a strategic reassessment to optimize its life insurance offerings through epigenetic science. Interim CEO Tyler Danielson highlighted efforts to realign operations and reduce costs, increasing access to liquidity after selling a non-core regulated insurance entity for over $4.7 million. The company has initiated sales of the FOXO Longevity Report™ in partnership with life insurance products and established relationships with over 3,000 independent agents. A conference call scheduled for March 30, 2023, will discuss these results.

FOXO Technologies Inc. (AMEX: FOXO) is set to report its financial results for the fourth quarter and full year ended December 31, 2022, after market close on March 30, 2023. The management will host a conference call at 3:15 p.m. Central time on the same day to discuss these results and recent business updates. Interested parties can access the call via webcast or by dialing in. FOXO specializes in commercializing epigenetic biomarkers to modernize the life insurance industry, employing artificial intelligence to analyze DNA methylation for health and aging insights.